A recent study found, in a large sample of Ashkenazi Jews, a highly significant association between schizophrenia and a particular haplotype of three polymorphic sites in the catechol-O-methyl transferase, COMT, gene: an IVS 1 SNP (dbSNP rs737865), the exon 4 functional SNP (Val158Met, dbSNP rs165688), and a downstream SNP (dbSNP rs165599). Subsequently, this haplotype was shown to be associated with lower levels of COMT cDNA derived from normal cortical brain tissue, most likely due to cis-acting element(s). As a first step toward evaluating whether this haplotype may be relevant to schizophrenia in populations other than Ashkenazi Jews, we have studied this haplotype in 38 populations representing all major regions of the world. Adding to our previous data on four polymorphic sites in the COMT gene, including the Val158Met polymorphism, we have typed the IVS 1 rs737865 and 3 0 rs615599 sites and also included a novel IVS 1 indel polymorphism, yielding seven-site haplotype frequencies for normal individuals in the 38 globally distributed populations, including a sample of Ashkenazi Jews. We report that the schizophrenia-associated haplotype is significantly heterogeneous in populations worldwide. The three-site, schizophrenia-associated haplotype frequencies range from 0% in South America to 37.1% in Southwest Asia, despite the fact that schizophrenia occurs at roughly equal frequency around the world. Assuming that the published associations found between the exon 4 Val158Met SNP and schizophrenia are due to linkage disequilibrium, these new haplotype data support the hypothesis of a relevant cis variant linked to the rs737865 site, possibly just upstream in the P2 promoter driving transcription of the predominant form of COMT in the brain. The previously described HindIII restriction site polymorphism, located within the P2 promoter, varies within all populations and may provide essential information in future studies of schizophrenia.
Several lines of evidence suggest that COMT is a strong candidate gene for susceptibility to schizophrenia. [1] [2] [3] [4] [5] [6] [7] [8] [9] Despite the genetic linkage and association studies that have found evidence for a schizophrenia susceptibility locus on chromosome 22 in the q11.1 region containing the COMT gene, the chromosome 22 results have been inconsistent, [10] [11] [12] [13] [14] though recently strengthened by a sib pair study by Williams et al. 15 The reasons for the difficulty in reproducing these results could include small sample size and/or low relative risk (both leading to low power to detect linkage or association), ethnically heterogeneous samples, and differences in the expression of neurocognitive deficits in individuals with schizophrenia, all in addition to the likely existence of genetic heterogeneity and/or oligogenic inheritance of susceptibility. To reduce the likelihood of low statistical power and to assure ethnic homogeneity, Shifman et al 1 studied an exceptionally large patient and control sample of a homogeneous population of Ashkenazi Jews and found a highly significant association of schizophrenia and a particular haplotype of the COMT gene. Their findings involved the G-G-G haplotype at the IVS 1 rs737865, exon 4 Val158Met, and downstream rs165599 polymorphic sites. The associations with schizophrenia shown by the noncoding SNPs were more significant than the association shown by the exon 4 Val158Met site; the association shown by the haplotype was even more significant. These results suggest that other sites in the gene or nearby may contribute to the susceptibility. In particular, regulatory region variation may be involved.
The COMT protein exists in two forms, a soluble form (S-COMT) translated from a short mRNA transcribed by the P1 promoter in intron 2 of the COMT gene, and a membrane-bound form (MB-COMT) translated from a long mRNA transcribed by the P2 promoter 5 0 of exon 1 ( Figure 1 ). [16] [17] [18] In the brain, the predominant COMT protein is MB-COMT. 17, 18 Bray et al 2 have recently shown that the two chromosomes are not equally represented in cDNA made from brain mRNA in individuals selected for heterozygosity at various SNPs. Their finding strongly suggests there are cis-acting factors operating on transcription and/or mRNA stability. Bray et al 2 conclude from the studies of rs165599 heterozygotes that 'it is either SNP rs165599 itself responsible for the observed differences [in expression] or one that is in very strong LD with it.' However, in their studies of samples selected for heterozygosity at multiple markers, the individuals probably heterozygous for the Shifman schizophrenia-associated haplotype had the greatest average differential expression, while those heterozygous at the exon 4 Val158Met plus rs737865 sites had a larger and more significant difference in expression than those heterozygous at the exon 4 Val158Met and rs165599 sites. 2 This emphasizes the importance of the haplotype identifying a subset of chromosomes with low expression and association with schizophrenia.
Our previous population genetic studies of the Val158Met site showed that it was polymorphic in all populations studied, but with quite varying allele frequencies depending on which population from which region of the world was considered. 19 Haplotype studies incorporating additional markers at COMT, including one in the P2 promoter (a HindIII site), further showed considerable variation in frequencies around the world. 3 However, those haplotype studies did not include two of the noncoding SNPs studied by Shifman et al 1 and Bray et al. 2 Thus, whether the G-G-G haplotype even exists in other populations was largely unknown. Moreover, the mRNA expression studies 2 showed that the strongest haplotype association involved an intron 1 SNP rather than a 3 0 SNP. This places increased emphasis on the P2 promoter, the one most important for COMT expression in the brain. Other studies involving the P2 HindIII SNP have not found an association with schizophrenia or not found differences in total COMT expression by genotype but different ethnic groups, small numbers of subjects, and only measures of total, not allele-specific, expression confound interpretation. 4, 20, 21 Thus, the P2 promoter polymorphism previously described 3 is a candidate for the relevant regulatory variation or at least a surrogate marker for an etiological variant within the P2 promoter.
As a first step toward evaluating whether this haplotype and the P2 promoter polymorphism may be relevant to schizophrenia in populations other than Ashkenazi Jews, we have undertaken to determine haplotype frequencies in diverse populations.
Materials and methods
As an extension of our earlier studies of COMT, we have now added three sites to our four other polymorphic sites previously studied (see Figure 1 ) in order to include all three SNPs of the schizophrenia-associated haplotype. 3, 19 Data on all seven sites are now reported on a total of 2058 individuals from 38 populations. Links to descriptions of the population samples can be found in ALFRED (the web-accessible ALlele FREquency Database, see Electronic-Database Information) associated with the allele and haplotype frequencies. Population samples analyzed for the first time for any of the COMT sites in this study are the Ashkenazi Jews, Chagga, Chuvash, Khanty, Komi Zyriane, and Samaritans. All studies were approved by the Yale University Human Investigations Committee and all samples were collected with informed consent. Previously studied polymorphisms were typed as described. 1, 3 The new IVS 1 InDel was typed by PCR followed by gel separation, and the rs737865 and rs165599 SNPs were typed by RFLP protocols. Typing protocols, as well as further details for all sites, and the allele and haplotype frequencies at each site for all populations can be found in ALFRED (see Table 1 for ALFRED site UIDs; the seven-site haplotype UID is SI000939V).
As originally described in Iyengar et al, 22 we used the primers for the human polymorphisms to amplify the homologous regions of DNA from at least one individual from at least three of the following species; chimp, bonobo, gorilla, orangutan, and gibbon. The products were then digested and/or sequenced to reveal the nucleotides corresponding to the presence or absence of the sites polymorphic in humans and thus, by inference, which human allele is the ancestral allele.
Haplotype frequency estimates were calculated using HAPLO, which implements the expectationmaximization (EM) algorithm. 23 These estimates were used to calculate three LD measures-the standardized pairwise disequilibrium statistic D 0 , the pairwise x, as well as D
2
, which is sometimes called r 2 . [24] [25] [26] The significance of the non-randomness among alleles (ie, of linkage disequilibrium) was evaluated with a permutation test. 25 
Results
All sites were polymorphic in all populations, except the IVS 1 rs737865 site in the South American populations. Genotypes existed in the expected Hardy-Weinberg ratios. Regional average heterozygosities are given in Table 1 . The allele frequencies for each biallelic site, the four SNPs, two InDels, and the recoded IVS 1 STRP are graphically depicted in Figure 2 and showed large differences among populations. The numerical allele frequencies at each site for all populations can be found in ALFRED under the site UIDs in Table 1 . The F st values for the seven biallelic sites were within the empirical distribution of F st values that we have determined for 172 sites. 27 Ancestral alleles for the four SNP and two InDel sites are given in Table 2 , along with the allele symbol synonyms and allele descriptions. At four of these sites only a single allelic variant was seen in our nonhuman primate samples. However, at the IVS 1 InDel and the rs16559 sites more than one allele was seen. All of the alleles seen in non-human primates at the IVS 1 InDel contained one or more copies of the 67 bp inserted sequence; therefore, the 1 (inserted) allele is the ancestral allele. For the rs165599 site, most of the non-human primates sequenced were homozygous for the G allele, including one gibbon. However, one orangutan was homozygous for the A allele, and two bonobos were heterozygous. Nonetheless, the ancestral allele appears to be the G allele.
The population frequencies of the three-site schizophrenia-associated haplotype vary widely around the world (Figure 3a) . We note that the allele and haplotype frequencies in our sample of Ashkenazi Jews are similar, for the three sites in common, to those found in the Ashkenazi control sample in Shifman et al. 1 The frequencies of the other seven haplotypes defined by these three sites also vary significantly around the world, as do the frequencies of haplotypes defined by all seven 'biallelic' sites (data in ALFRED, site UID SI000939V). There are only 37 haplotypes, out of 128 possible, that occur at 45% in more than one population (106 have non-zero frequency estimates). Of these 37 haplotypes, only four contain the -G --G -G haplotype studied by Shifman et al.
1 (The -is used to indicate the unspecified allele of a polymorphic site. Sites are ordered along the gene, beginning with the promoter HindIII site.) This haplotype is greatly subdivided by the other sites in all the populations in which the -G --G -G haplotype was estimated to occur ( Figure 3b ). a This SNP was also described by in a paper and erratum. 4, 5 b In this paper, we have recoded and analyzed the COMT tetranucleotide repeat in intron 1 as a biallelic system. With the exception of three alleles found in four individuals in the Chagga, the alleles of this STRP can be divided into primary ladder alleles that evenly follow the 4 base pair (bp) TAAA repeat unit and secondary ladder alleles that consist of 4 bp repeat units and a final 3 bp repeat unit that lacks the last A of the repeat. The three tertiary ladder alleles seen in the Chagga are of unknown sequence. Primary on-ladder alleles are combined as Allele O and all secondary and tertiary non-ladder alleles are combined as Allele N.
Figure 2 COMT allele frequencies in 38 human populations. The frequencies given are for the ancestral alleles at five of the seven polymorphic sites. The ancestral allele of the rs737865 site is the A allele. We chose to display the frequencies of the G allele because it is the allele present in the schizophrenia-associated haplotype of Shifman et al. 1 The ancestral allele of the IVS1 STRP was not determined and the frequencies of the on-ladder allele are given for this site. Populations are grouped by region as in Table 1 .
Linkage disequilibrium between pairs of biallelic sites was significant between many of the sites in many populations (Table 3 , Figure 4 ). Shifman et al 
.01) in our sample of Ashkenazi Jews.
Discussion
Since Shifman et al 1 found significant associations individually between both the IVS 1 rs737865 and 3 0 rs165599 sites and schizophrenia, but very weak association between the exon 4 Val158Met SNP and schizophrenia, they suggest that positive associations between the Val158Met SNP and schizophrenia are due to LD. The expression studies of Bray et al 2 shift the focus strongly toward the P2 promoter governing transcription of the mRNA found primarily in the brain. Bray et al 2 do not specify the ethnicity of the cortical brain samples from which they derived the COMT cDNA for allelic expression studies, although they are probably northern/western European. Their haplotype frequencies do not match exactly any single population. The frequencies are similar to those of the European or Southwest Asian populations we have studied, and quite different from those of African, East Asian, and Native American populations (data in ALFRED). We find that the IVS 1 rs737865 site is fixed or nearly fixed in three populations (Figure 2) . In 14 out of the remaining 35 population samples, including the Ashkenazi Jews, the exon 4 Val158Met SNP showed some LD with the IVS 1 rs737865 SNP, suggesting that, in these populations, any positive association between schizophrenia and the functional polymorphism could be due to its association with the IVS 1 rs737865 SNP. However, in most of our population samples, including all East Asian and Native American populations, there is no significant LD between the exon 4 Val158Met site and the IVS 1 rs737865 site; so LD cannot explain positive associations.
The IVS 1 rs737865 SNP does not have any evident functional relevance, but the HindIII SNP, only 2.2 kb upstream, is within the P2 promoter and could have functional relevance itself, and at least is a good surrogate marker for any variation within the P2 promoter, since the P2 promoter drives transcription of the membrane-bound form of COMT, the form that is more highly expressed in brain. The obvious question arises as to whether the association with schizophrenia seen by Shifman et al 1 and the expression level association seen by Bray et al 2 with the IVS 1 rs737865 SNP reflect LD with the promoter HindIII SNP. Both the x and D 2 pairwise measures of LD show weak to moderate, though often highly significant, LD between the promoter HindIII and IVS 1 rs737865 sites in 22 populations at Po0.05, including 16 populations at Po0.01, out of the 35 populations in which it could be calculated ( Figure  4 ). All the significant associations have the G allele of the IVS 1 rs737865 site associated with the A allele of the promoter HindIII site. Though not significant, in the Nasioi and Mexican Pima the opposite pattern exists, with the two A alleles preferentially together. Such differences could occasionally occur by chance, especially as the LD is not strong between these two sites. 28 As the HindIII and IVS 1 rs737865 sites are not in complete LD, they will not give the same association results with another marker or trait. Thus, any extrapolation as to an association of the promoter HindIII SNP with schizophrenia is not warranted by the LD values themselves.
Linkage disequilibrium statistics, however, do not fully explain the results of the expression study; the associations for specific alleles at two sites are not symmetric, as shown by conditional probabilities. 2, 3 As the conditional probabilities in Table 4 show, if one selects chromosomes with the G allele at the IVS 1 rs737865 site, the probability of having the A allele at the HindIII site is 1.0 or nearly so for almost all populations. In contrast, of the chromosomes with the A allele at IVS 1 rs737865 SNP, there will be many that also have the A allele at the HindIII site, as well as many with the G allele. Thus, if the HindIII promoter site, or one in complete LD, is the site controlling expression, these data predict that virtually all of the chromosomes with the G allele at the IVS 1 rs737865 site will have low expression of COMT, while chromosomes with the A allele at the IVS 1 rs737865 site will be a mixture, varying among populations, of high and low expression of COMT. The three-site schizophrenia-associated haplotype of Shifman et al 1 is only associated with a single P2 promoter HindIII allele. Interestingly, choosing haplotypes for the G allele at the 3 0 rs165599 SNP does not yield such homogeneity (data not shown). The conditional probabilities of the A allele at the HindIII site given the G allele at the 3 0 rs165599 site range from 0.976 (in Yemenite Jews) to 0.490 (in Samaritans). The Ashkenazi Jews have one of the higher values, 0.860. Therefore, it would not be too surprising if this site showed a stronger association with schizophrenia in a particular study of this population, since a slight change in allele and haplotype frequencies could alter the relative association levels of the IVS 1 and 3 0 SNPs with the promoter HindIII SNP.
The G allele at IVS 1 rs737865 is the derived allele and its strong association with only one of the P2 promoter alleles is consistent with its being more recent than the promoter polymorphism. The ubiquity of the IVS 1 rs737865 polymorphism argues that, although relatively more recent, its origin still predates expansion of modern humans out of Africa. This G allele is similarly more strongly associated with the exon 4 Val158Met G allele, also consistent with the more recent origin of the rs737865 polymorphism. Thus, the rs737865 G allele flags a more homogeneous set of haplotypes.
Several studies provide weak evidence against the HindIII SNP being the functionally relevant one. The Li et al study 4 of Chinese families with schizophrenia showed highly significant overtransmission of a haplotype with a specific HindIII allele ('G'), but also significant undertransmission of a different haplotype with the same HindIII allele. Considering only the P2 promoter HindIII site, they found nonsignificant preferential transmission of the 'A' allele. 20 it is possible that the schizophreniaassociated haplotype is in LD with another genetic polymorphism which affects COMT expression in a tissue-specific manner.
DeMille et al 3 found very little LD between the promoter HindIII site and the exon 4 Val158Met site (cf. . Moderate, but significant (Pr0.01), LD between the promoter HindIII and the exon 4 Val158Met sites exists in only seven out of 38 populations, the Yemenite Jews, Khanty, Taiwanese Chinese, Cheyenne, Arizona Pima, Maya, and Ticuna. Thus, functional variation in the promoter region may be distributed in populations largely independently of the Val158Met site. It is possible that the risk of schizophrenia is truly 'epistatic' in that both specific regulatory variation and the Val158Met activity difference interact to produce a gene whose overall function confers susceptibility. Such a hypothesis would explain the Shifman et al 1 results; a single haplotype incorporating the promoter HindIII site might show an even stronger association with schizophrenia.
Interestingly, the haplotype identified by Shifman et al 1 and Bray et al 2 has the presumptive 'low expression' allele at the P2 promoter and the G allele coding for Val, the 'high activity' allele, at the Val158Met site. However, it is not known directly whether the Val158Met polymorphism affects the activity of the membrane-bound form of COMT (MB-COMT) protein, the predominant form of COMT expressed in brain dorsolateral prefrontal cortical neurons. 29 We could find no studies of the effect of the Val158Met polymorphism on the thermostability or enzyme activity of MB-COMT. Lotta et al 30 studied the soluble COMT protein (S-COMT, the exon 4 Val/ Met polymorphism is located at amino acid 108 in S-COMT) and found no difference in the enzyme kinetics between the Val or Met variants. They did find that, in the absence of AdoMet/SAM, the cofactor in the methylation reaction, the Met (low activity, A, site present) allelic variant was thermolabile and the Val (high activity, G, site present) allelic variant was not. In the presence of AdoMet/SAM, there was no difference in the thermostability of the allelic variants. The exon 4 Val108Met amino acid, which is located on the opposite side of the S-COMT protein from the enzyme site, does not contribute to the active site, suggesting that conformational changes are not the cause of the thermolability and enzyme activity differences seen with the different amino acids at this site. However, Lotta et al 30 do note that there is a direct connection of an alpha-helix and beta-strand within the structure of S-COMT between amino-acid residue 108 and the binding groove for AdoMet.
Perhaps the Met variant of the S-COMT protein does have a different conformation that affects the binding of AdoMet/SAM. Lotta et al 30 also suggest that it is an interaction between a charged side chain on the COMT enzyme substrate and either the attached cellular membrane or the longer amino end of MB-COMT, rather than a conformational change in the protein structure, that causes the higher affinity of MB-COMT for dopamine. The higher affinity for dopamine of MB-COMT makes it more important than S-COMT at the physiological levels of dopamine found in the brain. It seems important to know whether the presence of the longer amino end of MB-COMT, or the adjacent cellular membrane, could stabilize the protein, as it seems to stabilize the enzyme/substrate interaction, and affect the thermostability of the Met allelic variant of MB-COMT, similar to the effect of AdoMet/Sam on the Met allelic variant of S-COMT.
The population variation in haplotype frequencies and associations of alleles at the different polymorphic sites of COMT highlight the difficulties of interpreting many of the published association studies that have examined only the Val158Met polymorphism. For example, in two recent studies ethnically heterogeneous samples without precise matching of the contrasted groups make the authors' conclusions impossible to accept based solely on the evidence presented: the question is raised whether population stratification could have resulted in an artifactual association. 31, 32 In a study of Japanese, an association was found with the maintenance dose of narcoleptics. 33 The difficulty in this case comes in trying to extrapolate to other populations with very different haplotype frequencies.
The Ashkenazi Jews are a well-defined homogenous population with a large founder effect, which decreases the likelihood of false positive association due to sample stratification and increases the likelihood that a true association between genotype at COMT and schizophrenia, a complex behavioral disorder, was found. In our study of 38 populations at seven polymorphic sites, we find (1) the same allele and haplotype frequencies as Shifman et al 1 at the three polymorphic sites, IVS 1 rs737865, exon 4 Val158Met, and downstream rs165599 SNPs, in our sample of Ashkenazi Jews; (2) the frequencies of alleles and haplotypes for these three sites vary significantly around the world; (3) the haplotype consisting of these three sites can be subdivided by any of the four other sites in ways that would likely provide more information for future association studies with schizophrenia; and (4) the IVS1 rs737865 G allele is almost completely associated with one allele of the HindIII site in the P2 promoter in most populations studied, while the IVS1 rs737865 A allele is found in combination with both promoter alleles.
This population study emphasizes the importance of using haplotypes in association studies, not just a single marker, because any single non-etiological marker can have very different associations with the etiological variable in different populations and even in different samples from the same population. Haplotypes decrease that source of variation among studies and can increase the power. By using haplotypes in a large sample population, the Shifman et al 1 study found a highly significant association between schizophrenia and COMT, with a focus on the rs737865 SNP at the 5 0 end of intron 1. The location of this SNP pointed to the COMT P2 promoter located only a couple of kb upstream. The results of our COMT seven-site haplotype study support the relevance of the COMT P2 promoter to schizophrenia. More importantly, the population data show that the schizophrenia-associated haplotype varies significantly in frequency around the world and has significant heterogeneity when other markers in COMT are also considered. These empiric observations must be considered in research study design and Table 1 . (Figure 2 ) and, therefore, the LD could not be calculated.
in attempts to reconcile data from studies of diverse populations.
Summary
Palmatier et al present a population genetic study of seven polymorphic sites at the COMT gene for samples of normal individuals from 38 populations around the world. They discuss the implications of their findings for future work aimed at explaining some intriguing recent reports implicating variation near the COMT gene in susceptibility to schizophrenia. We argue that behind the findings relating COMT with schizophrenia may be an as yet unidentified cisacting variant in a nearby regulatory region, which drives transcription of the main form of COMT found in the brain. 
